Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously Untreated Patients with Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
DRUG: TQB2303|DRUG: Rituximab
Overall response rate (ORR), 18 weeks
Objective Response Rate (CR+CRu), 18 weeks|Progression-free survival (PFS), 18 weeks|Event-free survival (EFS), 18 weeks|Duration of Response (DOR), 18 weeks|:Overall survival (OS), 18 weeks
The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously Untreated Patients with Diffuse Large B-cell Lymphoma